Financial Review: DiaMedica Therapeutics (NASDAQ:DMAC) and Marinus Pharmaceuticals (NASDAQ:MRNS)

companies based on the strength of their analyst recommendations, risk, valuation, earnings, institutional ownership, growth and dividends. Marinus and DiaMedica are small-cap medical companies. Marinus is the better stock because it has stronger analyst recommendations and less risk.

Which is the best stock among these two small-cap medical firms? We will compare these two companies based on their valuations, profitability, dividends and analyst recommendations.

Analyst Ratings

MarketBeat has reported the current ratings of Marinus Pharmaceuticals & DiaMedica Therapeutics.

Sell Ratings

Hold Ratings

Buy Ratings

Strong Buy Ratings

Rating Score

Marinus Pharmaceuticals






DiaMedica Therapeutics






Marinus Pharmaceuticals currently has a consensus target price of $24.29, which indicates a potential upside gain of 166.14%. DiaMedica Therapeutics' consensus price target is $10.00. This indicates a potential gain of 506.06%. Analysts clearly believe DiaMedica Therapeutics has a higher potential upside than Marinus Pharmaceuticals.

Institutional and Insider Ownership

Institutional investors own 86.9% the shares of Marinus Pharmaceuticals. Comparatively 28.1% DiaMedica Therapeutics' shares are held by institutional investors. Marinus Pharmaceuticals is owned by 4.1% company insiders. DiaMedica Therapeutics, on the other hand, has 5.6% of its shares owned by insiders. Strong institutional ownership indicates that hedge funds, endowments, and large money managers believe in a company's long-term potential.

Earnings and Valuation

This table compares the gross revenue, earnings-per-share and valuation of DiaMedica Therapeutics and Marinus Pharmaceuticals.

Gross Revenue

Price/Sales Ratio

Net Income

Earnings per Share

Price/Earnings ratio

Marinus Pharmaceuticals

25.48 Million


-$19.82 millions



DiaMedica Therapeutics



-$13.68 millions



DiaMedica Therapeutics' revenue is lower, but its earnings are higher than Marinus Pharmaceuticals. Marinus Pharmaceuticals trades at a lower Price-to-Earnings Ratio than DiaMedica Therapeutics. This indicates that DiaMedica Therapeutics is the more affordable stock.

Volatility and Risk

Marinus Pharmaceuticals' beta is 1.16. This means that its stock price is 16 percent more volatile than S&P 500. DiaMedica Therapeutics, on the other hand, has a beta value of 1.73. This means that its stock price is 73% volatile than S&P 500.


This table compares the net margins of DiaMedica Therapeutics and Marinus Pharmaceuticals. Also, it shows their return on equity.

Net Margins

Return on Equity

Return on Assets

Marinus Pharmaceuticals




DiaMedica Therapeutics




You can read more about it here:

DiaMedica Therapeutics is better than Marinus Pharmaceuticals in 8 out of 13 factors.

About Marinus Pharmaceuticals

Get Rating

Marinus Pharmaceuticals, Inc., a biopharmaceutical firm, is engaged in the development and marketing of neuropsychiatric therapies. The company's clinical-stage drug candidate, ganaxolone is a positive modulator that has been developed in three dose forms, including liquid, capsule and intravenous. The company was established in Radnor in August 2003.

DiaMedica Therapeutics

Get Rating

DiaMedica Therapeutics, Inc. is a biopharmaceutical firm in clinical stages that specializes in the development and commercialization of novel recombinant protein products. It is developing the DM199 candidate product, which focuses on acute ischemicstroke (AIS) as well as chronic kidney disease. offers a FREE daily email newsletter